"Mushrooms" For Depression: New Science | NEJM Clinician

Why It Matters

The trial tempers growing enthusiasm for psychedelic antidepressants, highlighting unresolved efficacy and safety gaps that could shape clinical guidelines and regulatory policy.

Key Takeaways

• Psilocybin trial showed 17% response vs 11‑12% placebo.
• Differences were not statistically significant after six weeks.
• Most participants recognized they received psilocybin, risking bias.
• Suicidal ideation occurred in 4% of psilocybin group.
• One case of persistent hallucinations raised safety concerns.

Summary

NEJM Clinician reports on a JAMA Psychiatry trial evaluating a single 25 mg dose of psilocybin for treatment‑resistant depression. The double‑blind study randomized 144 patients to psilocybin, a low 5 mg dose, or nicotinamide, aiming to mask allocation.

At six weeks, 17 % of the high‑dose group met response criteria versus 11‑12 % in the active‑placebo arms, a difference that failed to reach statistical significance. Moreover, most participants correctly guessed they received psilocybin, undermining the blinding and potentially inflating efficacy signals.

Safety signals were notable: suicidal ideation emerged in 4 % of the psilocybin cohort, compared with 1‑2 % on placebo, and one participant experienced persisting hallucinations. The commentator warned that hype has outpaced evidence.

The findings suggest that, without robust efficacy and safety data, prescribing psilocybin outside controlled research is premature, urging clinicians to await larger trials before integrating psychedelics into standard depression care.

Original Description

NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD, explains a trial investigating the efficacy and safety of psilocybin as a therapy for treatment-resistant depression. Read the key results and comment from Peter Roy-Byrne, MD clinician.nejm.org.